| Year |
Citation |
Score |
| 2019 |
Gao B, Lue HW, Podolak J, Fan S, Zhang Y, Serawat A, Alumkal JJ, Fiehn O, Thomas GV. Multi-Omics Analyses Detail Metabolic Reprogramming in Lipids, Carnitines, and Use of Glycolytic Intermediates between Prostate Small Cell Neuroendocrine Carcinoma and Prostate Adenocarcinoma. Metabolites. 9. PMID 31035489 DOI: 10.3390/Metabo9050082 |
0.598 |
|
| 2017 |
Lue HW, Podolak J, Kolahi K, Cheng L, Rao S, Garg D, Xue CH, Rantala JK, Tyner JW, Thornburg KL, Martinez-Acevedo A, Liu JJ, Amling CL, Truillet C, Louie SM, et al. Metabolic reprogramming ensures cancer cell survival despite oncogenic signaling blockade. Genes & Development. PMID 29138276 DOI: 10.1101/Gad.305292.117 |
0.33 |
|
| 2017 |
Podolak J, Eilers K, Newby T, Slottke R, Tucker E, Olson SB, Lue HW, Youngren J, Aggarwal R, Small EJ, Graff JN, Alumkal JJ, Beer TM, Thomas GV. Androgen receptor amplification is concordant between circulating tumor cells and biopsies from men undergoing treatment for metastatic castration resistant prostate cancer. Oncotarget. 8: 71447-71455. PMID 29069718 DOI: 10.18632/oncotarget.16169 |
0.485 |
|
| 2017 |
Podolak J, Eilers K, Newby T, Slottke R, Tucker E, Olson SB, Lue HW, Youngren J, Aggarwal R, Small EJ, Graff JN, Alumkal JJ, Beer TM, Thomas GV. Androgen receptor amplification is concordant between circulating tumor cells and biopsies from men undergoing treatment for metastatic castration resistant prostate cancer. Oncotarget. PMID 28415742 DOI: 10.18632/oncotarget.16169 |
0.485 |
|
| 2015 |
Lue HW, Cole B, Rao SA, Podalak J, Van Gaest A, King C, Eide CA, Wilmot B, Xue C, Spellman PT, Heiser LM, Tyner JW, Thomas GV. Src and STAT3 inhibitors synergize to promote tumor inhibition in renal cell carcinoma. Oncotarget. PMID 26625308 DOI: 10.18632/Oncotarget.5971 |
0.382 |
|
| 2011 |
Lue HW, Yang X, Wang R, Qian W, Xu RZ, Lyles R, Osunkoya AO, Zhou BP, Vessella RL, Zayzafoon M, Liu ZR, Zhau HE, Chung LW. LIV-1 promotes prostate cancer epithelial-to-mesenchymal transition and metastasis through HB-EGF shedding and EGFR-mediated ERK signaling. Plos One. 6: e27720. PMID 22110740 DOI: 10.1371/Journal.Pone.0027720 |
0.553 |
|
| 2008 |
Huang WC, Havel JJ, Zhau HE, Qian WP, Lue HW, Chu CY, Nomura T, Chung LW. Beta2-microglobulin signaling blockade inhibited androgen receptor axis and caused apoptosis in human prostate cancer cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 5341-7. PMID 18765525 DOI: 10.1158/1078-0432.Ccr-08-0793 |
0.653 |
|
| 2008 |
Zhau HE, Odero-Marah V, Lue HW, Nomura T, Wang R, Chu G, Liu ZR, Zhou BP, Huang WC, Chung LW. Epithelial to mesenchymal transition (EMT) in human prostate cancer: lessons learned from ARCaP model. Clinical & Experimental Metastasis. 25: 601-10. PMID 18535913 DOI: 10.1007/S10585-008-9183-1 |
0.472 |
|
| 2008 |
Arnold RS, Chung LW, Farach-Carson MC, Huang W, Lue H, Marshall FF, Opdenaker L, Osunkoya AO, Petros JA, Rogatko A, Sung S, Tighiouart M, True LD, Vessella R, Wang R, et al. PROSTATE CANCER BONE METASTASIS: REACTIVE OXYGEN SPECIES, GROWTH FACTORS AND HEPARAN SULFATE PROTEOGLYCANS PROVIDE A SIGNALING TRIAD THAT SUPPORTS PROGRESSION Journal of Urology. 179: 192-192. DOI: 10.1016/S0022-5347(08)60558-3 |
0.641 |
|
| Show low-probability matches. |